????. ?????????? ????????

????. ?????????? ????????

??Thank you for your votes

???????? ???????? ???? ???????????????????? ?????????????? ???? ???????????? ???? ???????

???????????9%

?????????????59%

???????????????29%

?????? ??+ ???????????????3%

??European Commission

??Agenda, 9. March 2023: Scientific Committees on Health, Environmental and Emerging Risks (SCHEER) 4th Plenary meeting (2022-2026)

Request for the update of Guidelines (see below) on the benefit-risk assessment of the presence of phthalates in certain medical devices covering phthalates, which are carcinogenic, mutagenic, toxic to reproduction (CMR) or have endocrine disrupting (ED) properties.

??Directive 2011/65/EU of the European Parliament and of the Council of 8?June 2011 on the restriction of the use of certain hazardous substances in electrical and electronic equipment (recast)

This is important for medical device manufacturers to monitor as a number of exemptions for materials listed in Annex III expire during 2023.

??COMMISSION STAFF WORKING DOCUMENT EVALUATION of Electromagnetic Compatibility Directive 2014/30/EC

For manufacturers of electrical and electronic medical equipment.

??Therapeutic Goods Administration

Guidance on the transitional arrangements and obligations

Reclassification of medical devices that are substances to be introduced into the body or applied to and absorbed by the skin.

??FDA

??Draft Guidance: Potency Assay Considerations for Monoclonal Antibodies and Other Therapeutic Proteins Targeting Viral Pathogens Guidance for Industry

??Guidance: Q13 Continuous Manufacturing of Drug Substances and Drug Products Guidance for Industry

This is the same as International Council for Harmonization (ICH) Quality guidance Q13 released November 2022.

??eMDR System Enhancements

For medical device manufacturers submitting eMDR reports via an AS2 Account with the FDA Electronic Submissions Gateway (ESG), be ready for Production Deployment of eMDR enhancements on March 17, 2023.


??Team-NB

Best Practice Guidance for the Submission of Technical Documentation under Annex II and III of In Vitro Diagnostic Medical Devices Regulation (EU) 2017/746

??MedDRA MSSO

Medical Dictionary for Regulatory Activities

Version 26.0 has been released (4 documents)

MedDRA is a standardized international medical terminology dictionary, providing a common language for the classification of medical information related to drug safety and regulatory activities, important for regulatory authorities, pharmaceutical companies, healthcare professionals, and patients. It helps improve the quality and consistency of adverse event reporting and other medical data, facilitating the identification of potential safety concerns and the development of appropriate risk management strategies, ultimately promoting the safety and efficacy of medicinal products and protecting public health.

??#RareDiseaseDay 28. February 2023

??Directive 2011/65/EU of the European Parliament and of the Council of 8?June 2011 on the restriction of the use of certain hazardous substances in electrical and electronic equipment (recast)

??European Commission.

This is an apology for inaction and an opinion looking forward:

??European Medicines Agency

A very useful factsheet:

??Department of Health and Social Care

??Medicines and Healthcare products Regulatory Agency

A very easy to follow Medical Device Registration Reference Guide:

??Swissmedic

??Guidance: Mobile Technologies

ZL000_00_040e_FO Mobile technologies?(DOCX, 171 kB, 01.03.2023)

ZL000_00_006e_VZ Directory Overview of documents to be submitted?(XLSX, 265 kB, 01.03.2023)

??Guidance: Document Packaging Texts Veterinary Products

ZL100_00_002e_FO Form New authorisation of veterinary medicinal products?(DOCX, 89 kB, 01.03.2023)

??Guidance: Document Packaging Human Medicinal Products

ZL000_00_048d_VL Fachinformation für Humanarzneimittel?(DOCX, 167 kB, 01.03.2023)

ZL000_00_049d_VL Patienteninformation für Humanarzneimittel?(DOCX, 165 kB, 01.03.2023)

ZL100_00_001e_FO Form New authorisation of human medicinal products?(DOCX, 196 kB, 01.03.2023)

??Guidance: Simplified Manufacturing Information

ZL300_00_003e_FO Form Variations and extensions?(DOCX, 509 kB, 01.03.2023)

ZL300_00_004e_FO Variations TAM?(DOCX, 536 kB, 01.03.2023)

??Guidance: Changes to establishment licences.

??Guidance:Third-party maintenance of software updates,Inspection, repair, preparation....

In German: Leaflet detailing guidance for third-party maintenance of software updates,Inspection, repair, preparation for first use and preparation for reuse,to maintain or restore the functional condition of a medical product.

??List of all countries with comparable control (of human medicinal products)

??European Medicines Agency

EMA has launched a pilot project to provide scientific advice on the intended clinical development strategy for ten selected high-risk?#medicaldevices .

??GOV.UK The Windsor Framework

"The agreement safeguards frictionless access to the EU market for world-leading Northern Ireland pharmaceutical and medical technology firms. This pragmatic dual-regulatory system protects business, patients and healthcare services, and reflects that it is an essential state function to maintain and oversee the supply of medicines within the whole United Kingdom"

- UK legislation applies to Northern Ireland rather than EU legislation BUT

- UK European Union #MDR and #IVDR apply to Northern Ireland.

- Medicines and Healthcare products Regulatory Agency to approve drugs for the whole UK market including Northern Ireland.

- If the product has only be approved in the UK then it should be marked "Not for Europe".

- Falsified Medicines Directive will NOT apply to Northern Ireland.

- Innovative drugs approval will be under UK regulatory system rather than managed by European Medicines Agency.

??Medical Device Authority Ministry Of Health, Malaysia (KKM)

FIRST EDITION GUIDANCE DOCUMENT MDA/GD/0064: NOTIFICATION OF CUSTOM-MADE MEDICAL DEVICES

A medical device made with a specific design characteristic in accordance with a healthcare professional’s written prescription and is intended to be used for a particular patient.

??Egyptian Drug Authority

??Good Manufacturing Practices Training Program and Technical Support for Technicians and Workers

The deadline for participation and payment of the training fee is?on Wednesday, March 9, 2023.

The training program is scheduled to start on?Sunday, March 12, 2023, for a period of?six training days.

??A training course to introduce the licensing procedures for pharmaceutical factories.

The deadline for participation and payment of the training fee is?on Sunday, March 12, 2023.

The training program is scheduled to start on?Monday, March 13, 2023.

#IVD #Invitrodiagnostic #IVDR #MDR

Prisca Zammaretti

Managing Director at SAQ as well as passionate Co-Active, ACC and ORSC Coach at Green Wave CC

1 年

Nice update Martin!

回复

要查看或添加评论,请登录

社区洞察